Spatial Genomics Market Current Progress, Growth Drivers, challenges, and Future Development

Spatial Genomics & Transcriptomics Market growth is the increasing adoption of spatial genomics and transcriptomics techniques for drug discovery & development and the increasing R&D investments and public-private funding. Additionally, introducing technologically advanced instruments for spatial genomics analysis boosts the market growth.

Currently, Spatial Genomics & Transcriptomics Market is growing at a Compound Annual Growth Rate (CAGR) of 17.6 % to reach USD 800 million by 2027. The spatial genomics and transcriptomics market is segmented into spatial transcriptomics techniques and spatial genomics analysis techniques. In 2021, the spatial transcriptomics techniques segment accounted for the largest share of the global spatial genomics and transcriptomics market. Growth in this market segment can be attributed to the high adoption of spatial transcriptomics in drug discovery and development, introduction of novel products, increasing R&D investments and public-private funding.

Request for assumptions & how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=170900551

Growth Drivers

Increasing adoption of spatial genomics & transcriptomics in drug discovery & development
Introduction of novel products
Increasing R&D investments and public-private funding

Growth Opportunities

Increasing use of spatial omics for biomarker identification

Challenges

Dearth of skilled professionals

Trends

Imaging-based technological advancements

The prominent players operating in the Spatial Genomics & Transcriptomics Market are

NanoString Technologies, Inc. (US), 10X Genomics (US), Illumina (US), Bio-Rad Laboratories (US), Bio-Techne Corporation (US), Genomic Vision SA (France),

NanoString provides life science tools for translational research. The company is engaged in developing, manufacturing, and commercializing instruments, consumables, and services for simultaneously profiling gene and protein activity from a single tissue sample. In 2019, the company launched the GeoMx Digital Spatial Profiler, enabling highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections. The company operates in the spatial genomics and transcriptomics market through its Product segment.

10x Genomics accounted for the second-largest share in the global spatial genomics and transcriptomics market in 2021. 10x Genomics offers the Visium Spatial platform and consumables such as Visium Spatial Gene Expression assays and Visium mRNA arrays to measure spatial gene expression patterns using high-density DNA barcode sequencing arrays. The company acquired Spatial Transcriptomics (Sweden) in 2018 and entered the spatial genomics and transcriptomics market. Its unique position and leadership in single-cell analysis have paved the way for developing spatial technologies. While the company does not offer spatial transcriptomic solutions at the single-cell level, its expertise offers 10x Genomics a competitive edge in the market.

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170900551

North America is expected to exhibit the highest growth during the forecast period

Rising focus on drug discovery & development,
Attributed to the growing incidence of chronic diseases and genetic diseases
The rapidly growing aging population,

Recent Developments

In 2022, NanoString and Abcam announced an agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomics solutions.
In 2022, 10x Genomics announced the first commercial shipments of its Xenium platform for analysis. Xenium is the next generation of targeted spatial profiling of genes and proteins at subcellular resolution.
In 2022, Illumina and AstraZeneca announced a strategic research collaboration to accelerate drug target discovery by combining their strengths in AI-based genome interpretation and genomic analysis techniques with industry expertise.